Epithalon
L-alanyl-L-glutamyl-L-aspartyl-glycine
Epithalon is a synthetic tetrapeptide consisting of four amino acids (Ala-Glu-Asp-Gly) developed by Khavinson and colleagues in Russia during the late 1980s. With a molecular weight of 390.35 g/mol, this compact peptide mimics a segment of the naturally occurring thymic peptide epithalamin extracted from pineal glands, making it a valuable tool for research into telomere elongation, pineal gland function, and cellular aging processes in controlled experimental settings.
Complete Research Database
Adverse Event Frequencies (Clinical Trials)
Clinical Safety Notes
- •GI side effects typically occur during dose escalation
- •Most adverse events are mild to moderate in severity
- •Discontinuation rate due to side effects: ~5.3%
- •No increased risk of pancreatitis in clinical trials
- •Regular monitoring recommended for thyroid function
Medical Disclaimer
Epithalon is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Long-term safety data in humans is extremely limited.